Evolus, Inc. (EOLS) financial statements (2020 and earlier)

Company profile

Business Address 520 NEWPORT CENTER DRIVE
NEWPORT BEACH, CA 92660
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments13093
Cash and cash equivalents11093
Short-term investments20 
Receivables11 
Inventory, net of allowances, customer advances and progress billings6 
Inventory6 
Other undisclosed current assets51
Total current assets:15294
Noncurrent Assets
Operating lease, right-of-use asset4
Property, plant and equipment1 
Intangible assets, net (including goodwill)8177
Goodwill2121
Intangible assets, net (excluding goodwill)6056
Other noncurrent assets20
Total noncurrent assets:8878
TOTAL ASSETS:240172
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:145
Accounts payable 2
Accrued liabilities 4
Employee-related liabilities5 
Other undisclosed accounts payable and accrued liabilities9 
Debt1 
Other undisclosed current liabilities9 
Total current liabilities:245
Noncurrent Liabilities
Long-term debt and lease obligation7717
Long-term debt, excluding current maturities7417
Operating lease, liability4
Liabilities, other than long-term debt 0
Deferred rent credit 0
Other undisclosed noncurrent liabilities5965
Total noncurrent liabilities:13782
Total liabilities:16187
Stockholders' equity
Stockholders' equity attributable to parent7984
Common stock00
Additional paid in capital293207
Accumulated other comprehensive income0 
Accumulated deficit(213)(123)
Total stockholders' equity:7984
TOTAL LIABILITIES AND EQUITY:240172

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
Revenues35 
Cost of revenue
(Cost of Goods and Services Sold)
(8) 
Gross profit:27 
Operating expenses(126)(46)
Operating loss:(99)(46)
Nonoperating income (expense)(6)0
Investment income, nonoperating20
Other nonoperating expense(8) 
Interest and debt expense (1)
Loss from continuing operations before income taxes:(105)(47)
Income tax expense (benefit)15(0)
Net loss available to common stockholders, diluted:(90)(47)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
Net loss:(90)(47)
Comprehensive loss:(90)(47)
Other undisclosed comprehensive income, net of tax, attributable to parent0 
Comprehensive loss, net of tax, attributable to parent:(90)(47)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: